This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Bimekizumab for non-radiographic axial spondyloarthritis

< Back

Bimekizumab for non-radiographic axial spondyloarthritis


Musculoskeletal, Orthopaedics

September 2021

Bimekizumab is in clinical development for the treatment of adults with non-radiographic axial spondyloarthritis (nr-axSpA). This condition affects patients predominantly in the spine and other areas of the body and is caused by inflammation. This inflammation can lead to back pain, fatigue and in serious cases, to severe disability as the bones of the spine fuse into a fixed position or joints become progressively damaged. It is characterised by an absence of radiographic sacroiliitis which is usually seen in patients with ankylosing spondylitis (AS). AS is also known as radiographic axial spondyloarthritis (r-axSpA). A proportion of patients with nr-axSpA will progress to AS. Some patients with nr-axSpA do not respond well to current treatment options, resulting in a clear unmet medical need.
Bimekizumab is a drug administered by subcutaneous injection that neutralises the function of certain proteins that regulate immune responses, interleukin (IL)-17A and IL- 17F cytokines. Neutralizing both IL-17A and IL-17F prevents them from interacting with their receptors (targets), which reduces skin and joint inflammation as well as pathological bone formation. If licensed, bimekizumab will provide an additional targeted treatment option for adults with nr-axSpA.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts